TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma.
about
Neoadjuvant chemotherapy in oral cancers: Selecting the right patientsTP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence.Increased growth-inhibitory and cytotoxic activity of arsenic trioxide in head and neck carcinoma cells with functional p53 deficiency and resistance to EGFR blockadeWee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapyReversible p53 inhibition prevents cisplatin ototoxicity without blocking chemotherapeutic efficacyA microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma.P53 nuclear stabilization is associated with FHIT loss and younger age of onset in squamous cell carcinoma of oral tongue.Sequencing the head and neck cancer genome: implications for therapyNovel biomarker panel predicts prognosis in human papillomavirus-negative oropharyngeal cancer: an analysis of the TAX 324 trial.Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cellsDisruptive TP53 mutation is associated with aggressive disease characteristics in an orthotopic murine model of oral tongue cancer.Prognostic Role of Circulating Tumor Cells during Induction Chemotherapy Followed by Curative Surgery Combined with Postoperative Radiotherapy in Patients with Locally Advanced Oral and Oropharyngeal Squamous Cell Cancer.Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence.Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer PatientsThe Role of p53 and MDM2 in Head and Neck Cancer.The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.Biomedical and biochemical applications of self-assembled metallacycles and metallacages.Phase II trial of induction chemotherapy followed by surgery for squamous cell carcinoma of the oral tongue in young adults.Elevated cyclin D1 expression is predictive for a benefit from TPF induction chemotherapy in oral squamous cell carcinoma patients with advanced nodal disease.Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.Oral Cavity Carcinoma: Current Management, Controversies, and Future Directions.Development of targeted therapy for squamous cell carcinomas of the head and neck.Targeted therapy vs. DNA-adduct formation-guided design: thoughts about the future of metal-based anticancer drugs.The mutational spectrum of squamous-cell carcinoma of the head and neck: targetable genetic events and clinical impact.Oncoapoptotic markers in oral cancer: prognostics and therapeutic perspective.Molecular biology and immunology of head and neck cancer.Biomarkers predicting chemotherapy response in head and neck squamous cell carcinoma: a review.Investigational drugs for head and neck cancer.MKP1 mediates chemosensitizer effects of E1a in response to cisplatin in non-small cell lung carcinoma cells.TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response.Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives.Exploiting the potential of autophagy in cisplatin therapy: A new strategy to overcome resistance.Reactive oxygen species and p21Waf1/Cip1 are both essential for p53-mediated senescence of head and neck cancer cells.Gain-of-function mutant p53 but not p53 deletion promotes head and neck cancer progression in response to oncogenic K-ras.Nedaplatin sensitization of cisplatin-resistant human non-small cell lung cancer cells.Current management of advanced resectable oral cavity squamous cell carcinoma.Quantitative analysis of nuclear shape in oral squamous cell carcinoma is useful for predicting the chemotherapeutic response.Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT.Comprehensive assessment of prognostic markers for sinonasal squamous cell carcinoma.
P2860
Q26768434-E0A28EA0-D043-47AB-AED1-AF7B29D60E4DQ27851687-9AD13F3C-10AC-4406-90A0-0BEBA202A31DQ28539684-E9F65478-A154-495B-A623-5031942E4861Q28833606-DCBB074E-7090-4CDD-8EC4-8EB6BF708E56Q30366115-B6ACBDEF-5FAA-4637-9FC1-A8440EF87371Q30497990-7C4A9540-954B-4EE0-963A-F3FDFA6E5583Q34079274-E2933BEB-C9D7-4AE9-AC38-9D18FD1B99ACQ35087559-DCBDEB89-3309-44DE-A4D9-0BEFA1367FE7Q35174609-F50F3FA5-A453-479B-BE7A-1AFDFC994A4AQ35184378-01D7C69E-9CDE-4091-A1CC-C94FCD7623C0Q35510945-07694DB8-8788-4495-8D08-EA6A6C7FC0A4Q35694837-B4240E29-6953-40E8-8E1C-B7696B25E940Q36020559-DCC88E19-706A-41F8-8C03-C19B7F2690F2Q36191292-628D81AB-E277-4319-B6DE-A2F59FD55457Q36857374-6E3C5D8C-46F2-47D7-AA9B-B923A825923FQ37228078-7BC94198-A32D-443D-AC0A-C9F0D23AF45CQ37325076-848A4498-04AA-4EC0-860E-7526EA57C1BBQ37483635-7F3148B1-ECBA-437B-9FEA-271C10851685Q37594771-F4B4F566-B876-4977-BB5B-A46FC76EC185Q37638784-AC65E11F-2805-4171-8E3B-04810314A535Q37658802-3A1058D6-C01F-4AA7-9A90-9CB48D9459EDQ37854706-92CF526F-AA9E-49D9-8121-251976C67EF4Q38011996-1F9A8768-C62D-41F7-90B3-18D71494EA25Q38203467-421B6464-8D18-4F5F-9791-3E38990198CDQ38212609-0E760F1B-A0C5-44AC-B27A-E9A2CD6D7997Q38483321-4B812CD0-83DB-46C3-A531-439C27E36AADQ38597457-88F87359-6668-46C6-8CB3-E7F749901168Q38800788-68416304-4E54-4DE0-A79E-6CF737E9CAAAQ38810052-46447B02-BC1B-412C-B3D8-DC7112E857FBQ38831709-30C80DCB-2595-4C64-9629-53AA54C3541EQ38838071-CB651082-1D41-49FE-9511-A49BD0BBA91EQ38868212-788E3580-5769-4C1D-9781-D3E62AEFAF71Q38900561-9547E528-E810-415B-9193-7CCE4BF86F45Q39467174-E0DE4148-CDF6-4C21-8C30-1DAF9BB58C57Q39644220-5A3AA2E4-BBBB-47FE-BB27-90CE7EF56568Q39764476-4E08BD91-B26C-4C53-846C-1438E63F696BQ40320022-2C4F3901-1020-4301-B43E-511E49FE171EQ41508310-10A4C60D-8092-428C-95A9-409C6A18D9A6Q44526398-95760BF3-A53F-43C8-BAC3-114F651A22E5Q46609517-E50284A1-DEE8-406F-A093-CFF7BEC8F56A
P2860
TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
TP53 mutations and pathologic ...... avity squamous cell carcinoma.
@en
TP53 mutations and pathologic ...... avity squamous cell carcinoma.
@nl
type
label
TP53 mutations and pathologic ...... avity squamous cell carcinoma.
@en
TP53 mutations and pathologic ...... avity squamous cell carcinoma.
@nl
prefLabel
TP53 mutations and pathologic ...... avity squamous cell carcinoma.
@en
TP53 mutations and pathologic ...... avity squamous cell carcinoma.
@nl
P50
P356
P1476
TP53 mutations and pathologic ...... cavity squamous cell carcinoma
@en
P2093
Barbara Cortelazzi
Silvana Pilotti
P304
P356
10.1200/JCO.2009.22.4170
P407
P577
2010-01-04T00:00:00Z